

Assistance Fund for Enrolled Patients

*Phase II trial of dasatinib in patients with
isocitrate dehydrogenase (IDH)-mutant
advanced intrahepatic cholangiocarcinoma*

Trial Sponsors and Collaborators

Massachusetts General Hospital
Bristol-Myers Squibb
TargetCancer Foundation

Trial Principal Investigator

Andrew X. Zhu, MD, PhD
Massachusetts General Hospital

TargetCancer Foundation promotes the development of lifesaving treatment protocols for rare cancers. Additionally, the foundation supports patient assistance initiatives. Enrolled patients in this clinical trial may be eligible for reimbursement of trial-related expenses, such as lodging, meals, and parking.

**For more information
on reimbursable expenses,
please contact:**

Jim Palma
Executive Director, TargetCancer Foundation
jim@targetcancerfoundation.org
617-765-4881



TargetCancer
Foundation